Clinical Trial Update: Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nebulized IVX-0142 for efficacy and safety in mild allergic asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• IVX-0142

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma | Phase 2 | Status: COMPLETED